Ursodeoxycholic acid for the treatment of primary biliary cirrhosis
| Autor: | Renée E. Poupon, Eveline Eschwège, Raoul Poupon, R. Poupon, R.E. Poupon, E. Eschwège, P. Attali, J.P. Capron, S. Erlinger, M. Beaugrand, J.C. Trinchet, F. Blanc, E. Vaucher, P. Calès, D. Capron-Chivrac, C. Plane, Ph. Cassan, T. Morin, J.C. Chaput, T. Poynard, P. Couzigou, Y. Deugnier, P. Brissot, D. Dhumeaux, J.M. Métreau, F. Degos, J.P. Etienne, C. Buffet, H. Fouin-Fortunet, A. Gauthier, P.M. Huet, B. Willems, V.G. Lévy, J.P. Miguet, P. Opolon, O. Bousquet, G. Parelon, H. Michel, E.A. Pariente, J.C. Paris, J.Ph. Ancelin, Y. Calmus, A. Valla, J.C. Verwaerde, G. Paumgartner, C. Degott, S. Zafrany, P. Callard, B. Balkau, Y. Chrétien, B. Pineau, P. Grand, P. Morselli, C. Claussmann |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
medicine.medical_specialty
Hepatology Bile acid business.industry medicine.drug_class Biliary cirrhosis Jaundice medicine.disease Interim analysis Placebo Gastroenterology Ursodeoxycholic acid law.invention Primary biliary cirrhosis Randomized controlled trial law Internal medicine medicine medicine.symptom business medicine.drug |
| Zdroj: | Journal of Hepatology. 11:16-21 |
| ISSN: | 0168-8278 |
| DOI: | 10.1016/0168-8278(90)90265-s |
| Popis: | Based on uncontrolled observations, we have proposed Ursodeoxycholic acid (UDCA) as a novel therapeutic approach in primary biliary cirrhosis (PBC). To confirm and extend our original findings, we have designed a double-blind multicentre randomized clinical trial. An interim analysis was planned at 6 months, involving all subjects included in the trial, with a final analysis at 2 years. The UDCA-PBC trial began in June 1987 and will be completed in March 1990. Seventy patients were randomized to receive UDCA and 68 a placebo. The two groups were well matched with respect to age, sex, duration and prevalence of symptoms and histologic severity (50% of the UDCA group had stage III–IV disease vs. 37% of the placebo group). During the first 6 months of follow-up, six patients withdrew from the trial. At 6 months, the proportion of patients with jaundice was significantly lower ( p p p p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|